Results 11 to 20 of about 186,761 (273)
Real-world outcome of neoadjuvant therapy with or without pembrolizumab for triple-negative breast cancer [PDF]
Acta OncologicaBackground and purpose: Neoadjuvant therapy (NAT) has become standard therapy for early triple-negative breast cancer (TNBC). The aim of this study was to report real-world outcome of TNBC treated with NAT with or without pembrolizumab and to identify ...
Johanna Mattson +7 more
doaj +2 more sources
Frontiers in Pharmacology, 2021 Background: Pembrolizumab is a guideline-recommended, both first- and second-line treatment option for microsatellite-instability-high (MSI-H)/mismatch repair-deficient (dMMR)advanced colorectal cancer patients.
Tan Chongqing +15 more
doaj +1 more source
Journal of Cancer Research and Clinical Oncology, 2022 AbstractThe current approval indications for pembrolizumab are complex, reflecting the inclusion criteria of numerous clinical trials that led to approvals. Here we argue that allowing the use of pembrolizumab to any advanced solid tumor in any tumor type in any line of therapy for a fixed duration may be preferable to the current assortment of ...
Kim, Myung S, Prasad, Vinay
openaire +4 more sources
Journal for ImmunoTherapy of Cancer, 2015 The development of the cytotoxic T-lymphocyte-associated protein 4 inhibitor ipilimumab and its approval in 2011 for the treatment of metastatic melanoma has heralded a new era in immuno-oncology. Subsequently, novel agents against the programmed death receptor 1 (PD-1)/programmed death receptor ligand 1 (PD-L1) axis have shown significant activity in ...
Khoja, Leila +4 more
openaire +2 more sources
Efficacy of pembrolizumab rechallenge for metastatic urothelial carcinoma
IJU Case Reports, 2022 Introduction Before the approval of enfortumab vedotin, no standard treatment was available as the salvage treatment for patients with metastatic urothelial carcinoma who had failed second‐line or later pembrolizumab.
Nobutaka Nishimura +5 more
doaj +1 more source
Pembrolizumab (Keytruda) [PDF]
Human Vaccines & Immunotherapeutics, 2016 The programmed cell death protein 1 (PD1) is one of the checkpoints that regulates the immune response. Ligation of PD1 with its ligands PDL1 and PDL2 results in transduction of negative signals to T-cells. PD1 expression is an important mechanism contributing to the exhausted effector T-cell phenotype.
Tse, EWC +4 more
openaire +4 more sources
Blinatumomab and Pembrolizumab [PDF]
Hospital Pharmacy, 2015 The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and investigational, used to treat malignant diseases.
Emily E, Tabor +2 more
openaire +2 more sources
Frontiers in Pharmacology, 2021 Objective: This network meta-analysis will provide a complete toxicity profile, toxicity profile, and safety ranking of immune checkpoint inhibitors (ICIs) for treatment of advanced non-small cell lung cancer (NSCLC).Methods: We found 12 phase II or III ...
Weidong Zhang +3 more
doaj +1 more source
Phase II Trial of IL-12 Plasmid Transfection and PD-1 Blockade in Immunologically Quiescent Melanoma. [PDF]
, 2020 PurposeTumors with low frequencies of checkpoint positive tumor-infiltrating lymphocytes (cpTIL) have a low likelihood of response to PD-1 blockade.
Algazi, Alain P +23 more
core +2 more sources
Current Oncology, 2022 Anaplastic thyroid carcinoma (ATC) are highly aggressive malignant tumors with poor overall prognosis despite multimodal therapy. As ATC are extremely rare, no randomized controlled study has been published for metastatic disease.
Laurys Boudin +5 more
doaj +1 more source